Drug Trial Radar · NCT06415773
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
367
Actual
Start
Jun 4, 2024
Primary completion
Jun 13, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
HTD1801Drug
HTD1801 1000 mg BID administered orally BID as four capsules
DapagliflozinDrug
Dapagliflozin 10 mg tablet administered orally QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint: Mean change in HbA1cTime frame: 24 Weeks
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Beijing Pinggu Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Binzhou Medical University Hospital
Binzhou, China
Jilin Province FAW General Hospital
Changchun, China
The Second Hospital of Jilin University
Changchun, China
The First People's Hospital of Changde City
Changde, China
The First Hospital of Changsha City
Changsha, China
The Fourth Hospital of Changsha
Changsha, China
The Second Xiangya Hospital of Central South University
Changsha, China
The Third Xiangya Hospital of Central South University
Changsha, China
Bishan Hospital of Chongqing
Chongqing, China
People's Hospital of Deyang City
Deyang, China
Handan First Hospital
Handan, China
The Fourth Hospital of Harbin Medical University
Harbin, China
The Second People's Hospital of Huai'an
Huai'an, China
Huanggang Central Hospital
Huanggang, China
Huangshi Central Hospital
Huangshi, China
Huizhou Municipal Central Hospital
Huizhou, China
Jincheng General Hospital
Jincheng, China
Hebei Petro China Central Hospital
Langfang, China
The Second People's Hospital of Lianyungang
Lianyungang, China
Liaocheng People's Hospital
Liaocheng, China
Luoyang Third People's Hospital
Luoyang, China
The First Affiliated Hospital of Henan University of Science & Technology (Jinghua)
Luoyang, China
The First Affiliated Hospital of Henan University of Science & Technology (Kaiyuan)
Luoyang, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Nanjing Drum Tower Hospital - The Affiliated Hospital of Nanjing University Medical School
Nanjing, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, China
Panjin Liaohe Oilfield GEM Flower Hospital
Panjin, China
Pingxiang People's Hospital
Pingxiang, China
The First Hospital of Qiqihar
Qiqihar, China
Sanmenxia Central Hospital
Sanmenxia, China
Huadong Hospital Affiliated to Fudan University
Shanghai, China
Shanghai Sixth People's Hospital
Shanghai, China
Shengjing Hospital of China Medical University
Shenyang, China
The People's Hospital of Liaoning Province
Shenyang, China
Wuhan Third Hospital
Wuhan, China
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.